The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer

December 17, 2014 updated by: Ronald Zweemer, UMC Utrecht

Objective of the study: To study the concordance of sentinel node (SN) localization between preoperative Magnetic Resonance Lymphangiography and SPECT-CT SN mapping and the intra-operative SN procedure for low stage cervical cancer.

Background: The SN procedure for surgically treated cervical cancer is promising. Unfortunately, efficient and direct intra-operative SN localisation, without an extensive surgical exploration, remains a challenge even with combined use of patent blue dye en technetium-99m (99mTc). Preoperative imaging (= mapping) with 99mTc based SPECT-CT, which is increasingly adopted, has partly alleviated this problem. The investigators aim to investigate the feasibility of a new SN mapping modality, which visualises the (sentinel) lymph nodes using a Magnetic Resonance Imaging (MRI) technique (so called; Magnetic Resonance Lymphangiography), and compare it to SPECT-CT.

Design: Prospective, feasibility type diagnostic study. 40 subjects targeted. Via vaginal speculum exam, a specific MRI contrast-agent will be intracervically injected. Subsequently, on a wide bore 1.5T MRI system multiplanar imaging is performed, followed by a blinded review (experienced radiologist) for bilateral SN localization. Standard care with a preoperative SPECT-CT (after intracervical 99mTc administration). A blinded nuclear medicine specialist will localize the SN on the SPECT-CT images. Open or (robot-assisted) laparoscopy performed for localization of the blue stained and/or 99mTc-hot SN. Excision of the SN with freeze sectioning and histological review. Statistical analysis with intrapatient testing for concordance of MR Lympangiography and SPECT-CT based SN localization against the reference standard: the intra-operative sentinel node procedure.

Study Overview

Detailed Description

Background of the study: The sentinel procedure (SN) for surgically treated cervical cancer is promising. Unfortunately, efficient and direct intra-operative SN localisation, without an extensive retroperitoneal exploration, remains a challenge even with combined use of patent blue dye en 99mTc. The draining lymph nodes are positioned around the retroperitoneal pelvic vasculature, in close relation to the ureters and nerves innervating bladder, rectum and sexual functionality (inferior hypogastric plexus, genitofemoral nerve, etc), which makes exploration hazardous and time consuming. Furthermore, complete retroperitoneal exploration often necessitates dissection of lymph vessels (to find the SN) which would have been spared in a selective SN excision. The use of technetium-99m(99mTc) enables preoperative SN mapping with SPECT(-CT) to localise SN and partly alleviate this issue. Some clinics perform preoperative SPECT(-CT), despite its disadvantages of prolonged hospital admission, radiation exposure, limited spatial resolution (SPECT) and the limited soft tissue differentiation in the female pelvis (CT). The investigators postulate that Magnetic Resonance (MR) Lymphangiography is a better technique for preoperative SN mapping in cervical cancer. It allows for integration with regular work-up pelvic MRI and could make SPECT-CT unnecessary.

Objective of the study: To study the concordance of sentinel node localization between preoperative MR Lymphangiography and SPECT-CT SN mapping and the intra-operative sentinel node procedure (patent blue and 99mTc) for low stage cervical cancer.

Study design: Prospective, feasibility type diagnostic study with the experimental test (MR Lymphangiography) added to standard clinical care (SPECT-CT, intra-operative SN procedure).

Methods: 40 subjects targeted. Via a vaginal speculum exam 1ml of MR contrastmedium will be intracervically injected peripheral of the cervical tumor at 3, 6, 9 and 12 o'clock (suspine position). On a wide bore digital 1.5T MRI multiplanar T1w imaging is performed, followed by a blinded review (experienced radiologist) for bilateral SN localization with a standardized anatomical system. Standard procedure with a preoperative 220 MBq 99mTc SPECT-CT, a blinded nuclear medicine specialist will localize the SN. Standard peri-operative care; under general anesthesia 1ml injection of patent blue V in each of the four quadrants. Open or (robot-assisted) laparoscopy performed for visual localization of the blue SN's. Introduction of a gamma-probe and localization 'hot and blue' SN. For both methods anatomical locations of the SN are registered. Excision SN for freeze sectioning and histological review. Statistical analysis with intrapatient testing for concordance of SPECT-CT and MR Lympangiography based SN localization against the reference standard: the intra-operative sentinel node procedure (Patent blue and 99mTc).

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Utrecht, Netherlands, 3508 GA
        • UMC Utrecht

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Adult patients with histologically proven cervical cancer which are a candidate for surgery, which includes an intra-operative SN procedure and pelvic lymph node dissection. Subjects are derived form a tertiary referral center.

Description

Inclusion Criteria:

  1. Histologically proven primary malignancy of the cervix uteri;
  2. Primary therapy is surgery with minimally an intra-operative SN procedure and pelvic lymph node dissection;
  3. ≥18 years of age and written inform consent provided.

Exclusion Criteria:

  1. Contra-indications to MR lymphangiography, defined as:

    • All MRI incompatible electronic and/or ferromagnetic objects;
    • Presence of any object in the pelvic area prohibiting good image quality;
    • Severe claustrophobia;
    • Pregnancy or breastfeeding;
    • Unable to lie still and in complete supine position for 45 minutes;
    • Body weight >150kg;
    • History of an allergic reaction to any gadolinium based contrast agent;
    • Renal disease with a glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m2;
  2. History of an allergic reaction to patent blue V dye;
  3. Any type of neo-adjuvant chemo and/or radiotherapy for cervical cancer;
  4. Altered anatomy of pelvic lymph nodal drainage system (e.g. history of retroperitoneal pelvic surgery or trauma).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
All patients
Alle subjects included retain in one cohort.
sentinel node localisation using the nuclear medicine technique SPECT-CT
Other Names:
  • Computed Tomography
  • Single Photon Emission Computed Tomography
Sentinel node localisation using Magnetic Resonance Lymphangiography
Open or (robot-assisted) laparoscopic sentinel node detection and resection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Level of concordance in sentinel node (SN) localization between Magnetic Resonance Lymphangiography and SPECT-CT SN mapping with the intra-operative SN detection (based on blue dye and Tc-99m-nanocolloid).
Time Frame: within 1 week
within 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The absolute number of SN detected and uni/bilateral SN detection rates by MR lymphangiography, SPECT-CT, intra-operative SN procedure with patent blue only and combined patent blue / 99mTc.
Time Frame: within 1 week
within 1 week
The false negative rates in SN localization by MR lymphangiography, SPECT-CT, intra-operative SN procedure with patent blue only and combined patent blue / 99mTc.
Time Frame: within 1 week
within 1 week
Disagreement between the; concordance SN localization SPECT-CT and intra-operative SN procedure (blue + 99mTc) with the concordance MR lymphangiography and intra-operative blue dye only SN procedure (strategy without 99mTc).
Time Frame: within 1 week

The difference in concordance (imaging to intra-operative results) between two strategies are compared.

  • The 1st strategy entails preoperative imaging with SPECT-CT and 'standard' intra-operative SN procedure (= with 99mTc use).
  • The 2nd strategy is with preoperative MR lymphangiography and an intra-operative 'blue dye only' SN procedure (= without 99mTc).
within 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ronald Zweemer, MD PhD, UMC Utrecht

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (Anticipated)

April 1, 2016

Study Completion (Anticipated)

April 1, 2016

Study Registration Dates

First Submitted

January 17, 2013

First Submitted That Met QC Criteria

January 23, 2013

First Posted (Estimate)

January 28, 2013

Study Record Updates

Last Update Posted (Estimate)

December 18, 2014

Last Update Submitted That Met QC Criteria

December 17, 2014

Last Verified

December 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on SPECT-CT sentinel node mapping

Subscribe